Vermillion Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
8,819.00
19,209.00
19,115.00
14,968.00
10,497.00
11,371
Depreciation, Depletion & Amortization
72.00
141.00
291.00
723.00
786.00
675
Other Funds
422.00
717.00
874.00
1,185.00
1,443.00
1,112
Funds from Operations
8,325.00
18,351.00
17,950.00
13,060.00
8,268.00
9,584
Changes in Working Capital
101.00
1,543.00
415.00
903.00
139.00
217
Net Operating Cash Flow
8,224.00
16,808.00
18,365.00
13,963.00
8,129.00
9,367
Capital Expenditures
321.00
258.00
1,055.00
1,261.00
60.00
Net Investing Cash Flow
321.00
258.00
1,055.00
1,261.00
60.00
Issuance/Reduction of Debt, Net
-
-
1,082.00
1,819.00
217.00
Net Financing Cash Flow
30,042.00
10,527.00
15,097.00
1,824.00
8,486.00
Net Change in Cash
21,497.00
6,539.00
4,323.00
13,400.00
297.00
Free Cash Flow
8,545.00
17,066.00
19,420.00
15,224.00
8,189.00
Change in Capital Stock
30,042.00
10,527.00
16,179.00
5.00
8,703.00

About Vermillion

View Profile
Address
12117 Bee Caves Road
Austin Texas 78738
United States
Employees -
Website http://www.vermillion.com
Updated 07/08/2019
Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. The company's bio-analytical solutions helps physicians diagnose, treat and improve gynecologic health outcomes for women.